Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc is projected to experience significant revenue growth driven by its Signatera testing, which is expected to see increased demand in both clinical settings and global biopharmaceutical applications. The company reported a substantial quarter where it achieved a revenue beat of approximately $80 million, alongside a notable year-over-year increase of 54% in Signatera MRD volumes, translating to an addition of 21,500 tests from the previous quarter. Additionally, Natera's expansion of reimbursement coverage for its oncology tests is anticipated to enhance average selling prices and support improved gross margins and operating cash flow in the future.

Bears say

Natera has expressed concerns regarding potential margin erosion due to reductions in in-network pricing as new commercial payors begin to offer their coverage, which may expand the target addressable market but also pressure profitability. The company is also at risk from various negative developments, such as regulatory setbacks or disappointing financial performance, which could have a significant adverse impact on its stock value. Furthermore, competitive pressures from firms like Guardant Health, coupled with challenges in international expansion and reimbursement issues, add to the uncertainty surrounding Natera’s growth and financial stability.

Natera (NTRA) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 14 analysts, Natera (NTRA) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $253.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $253.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.